You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Boehringer Ingelheim
Harvard Business School
Colorcon
Merck

Last Updated: October 22, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,691,185

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,691,185 protect, and when does it expire?

Patent 8,691,185 protects VIZAMYL and is included in one NDA.

This patent has fifty-nine patent family members in nineteen countries.

Summary for Patent: 8,691,185
Title:Benzothiazole derivative compounds, compositions and uses
Abstract: This invention provides benzothiazole derivative compounds, compositions comprising such compounds, methods of preparing such compounds, and methods of using such compounds for detecting amyloid deposit(s) and for diagnosing a disease, disorder or condition characterized by amyloid deposit(s).
Inventor(s): Klunk; William E. (Pittsburgh, PA), Mathis, Jr.; Chester A. (Pittsburgh, PA), Wang; Yanming (Imperial, PA)
Assignee: University of Pittsburgh--Of the Commonwealth System of Higher Education (Pittsburgh, PA)
Application Number:13/548,014
Patent Claim Types:
see list of patent claims
Use; Delivery; Formulation;

Drugs Protected by US Patent 8,691,185

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 DISCN Yes No   Start Trial   Start Trial DIAGNOSTIC RADIOIMAGING   Start Trial
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes   Start Trial   Start Trial DIAGNOSTIC RADIOIMAGING   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,691,185

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2001286702   Start Trial
Australia 2004221897   Start Trial
Australia 2008202626   Start Trial
Australia 2011200667   Start Trial
Australia 8670201   Start Trial
Brazil 0113470   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Moodys
McKesson
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.